Nice to see the Improved Financials out today!!!

It has always amazed me how much under the radar this stock really is. The capitalization value is so low, it just is not followed enough for good or bad news to effect it much. This is quite good news. People in the Parkinson's arena also recognize that any study of efficacy that must be done over a long period can be weighted downward by the tendency for the disease to have naturally progressed at various rates among the trial patients. i.e. - halting deterioration would be a positive sign, near 50% improvement is more than that.

The news is not really out much yet though. Although in the Parkinson's Parkinson's News Today, they put this out today:

https://parkinsonsnewstoday.com/2021/07/01/stem-cell-therapy-shows-safety-potential-efficacy-in-early-clinical-trial/

This company has appeared to be very undervalued most of its existance, IMHO. Yes there is some other classes of stock and options that will increase the total effective outstanding share count, but even then it will be fairly low comparatively. This is a development company that has actually produced some income and learned how to make and market their own produces while performing good science and development. More power to them. I hope for their sake and humanity they are even much more successful in the near and long term.

They have been quite silent compared to previous years. I hope they are just conserving cash and maintaining basic and profitable lines going.

On the research end they indicated the following in their most recent report: “””””” In April 2019, we announced the completion of subject enrollment, with the 12th subject receiving a transplantation of the highest dose of cells. There have been no safety signals or serious adverse effects seen to date as related to the transplanted ISC-hpNSC® cells. We anticipate providing full results of the active and follow up periods of the phase I clinical study in the second quarter of 2021.”

They have an annual meeting coming up that will be virtual only due to ongoing Covid activity. Their notice says; “””This year’s annual meeting of stockholders will be held on Wednesday, June 9, 2021, at 10:00 a.m. Pacific Time. Due to the public health concerns arising from the COVID-19 pandemic, the Annual Meeting will be a completely virtual meeting of stockholders. You can attend the Annual Meeting by visiting www.proxydocs.com/ISCO “”””

Can we get a prelist for SNMN for $1000.00??

Secondary holding with flatwave moving. Not sure if it means it will happen or not. But still considering what it would level to.

I am confused by what appears to be a positive outlook by many posting that also provide information that would appear contrary to a positive outlook.

What is the bottom line investment opinion of SMNM at this current juncture?

Years ago shares were cancelled out. I still have some of those on some books that are not tradable. I have a few others that I think still might be that were issued later, but maybe those are dead too.

I have not looked at this for a long long time...

Take care all... Have a good Christmas, but stay smart/safe!

Interesting new study:

Parkinsons may start before birth iPSCs

Interesting new study:

insert-text-here

https://www.cedars-sinai.org/newsroom/parkinsons-disease-may-start-before-birth/

Eischelman! Could it be? or is it just a response to the undervalued state of ISCO?

That is a red herring if I ever saw one. Very little if anything to do with ISCO.

20K for the Eischelman papers? Are the advancing for ISCO?

The FDA does some good things, but they also force a lot of bullshit and costs that get in the way of human trials. ISCO went to Australia to avoid all that and get their therapeutic into 12 humans as soon as practical. All 12 had well tolerated procedures which is great. The FDA also considers safety and efficacy data from credible institutions around the world, such as the Florey Institute of Neuroscience in Australia, when evaluating further studies along the same or related lines.

Actually Correct.

You are actually wrong.
KarinCA is actually quite correct.
Actual scams do not actually intracranially transplant stem cells into the human brain successfully in a world renowned neurological medical facility.
ISCO may sink or swim. But it is not a scam.

That is precisely it. He fully understands that. Was discussed in detail by ISCO. I don't quite understand why he insists on placing a potato chip company standard on ISCO. It just does not apply.

Seems like confusion over too many potato chips. ISCO is not in the potato business. They are in the medical therapeutics business via stem cell technology.

Looks like a good year end report to me. I don't see any reason for negativity. Sad that it seems that is all some wish to see and hear these days. Kudos to ISCO for a good year end report and the exchange upgrade. If the subs continue to improve, they alone are worth today's capitalization and more. Oh well, go figure, still flying too low under the radars I guess.

Good News going to OTCQX. That is the top tier on the OTC.

https://finance.yahoo.com/news/otcqx-vs-otcqb-vs-pink-171211773.html

Little pieces here and there keep coming together for this company. The new patent is good to have. Active cosmetics can grow to be a huge seller with good margins in a vanity driven society. Continued growth is indicative of positive acceptance.

Good to see the 60000+ volume today. One of the highest with this latest outstanding level.

I wish Fox would look at this for whatever potential it could provide to him and others. I sent his foundation a message a while back, but I bet they thought it a self serving stock promotion, even though I demonstrated it would not be with my level of investment. Maybe I will send them/him another note with the latest results.

Regardless, ISCO seems to be doing what they need to do to get where they should be. Nothing is for certain however. Nothing but the final curtain I guess.

Take care and good luck here and everywhere.

The next 2 years should be interesting........

HS

Once again....All Positive!

Not over the top mega millions unbelievable growth and technology development, but slow steady 'do what we say we are going to do', real stable growth and improvements, year after year. I am still quite surprised at how far ISCO flies under the radar. Better volume today, which may lead to more recognition. Hopefully the good story news of ISCO will reach more mainstream investing media. They need to transplant Michael J Fox........

I hope this company finally reaches a point of 'activation energy', brought on by wider news reach, brought on by undeniable value.

I also must provide the same disclaimer I have in the past, that is I am not a medical doctor, nor do I hold a doctoral degree in a specific subject. My alias relates to the Asimov creator of psychohistory, a mathematical model of human populations. Everything I ever write is just thoughts on my head at the moment and only one man's opinion.

My personal work did include research in a variety of areas that included the design and operation of scientific experiments. I enjoy researching a range of issues in a variety of the sciences. I find many recent medical advances fascinating. I think ISCO technology is real and meaningful. But it could still be usurped by something even newer and greater at almost any point. Many technologies are advancing in ways that they are complimenting each other and leading to wider applications, sprouting others. Even ones that influence the cellular level.

I am really glad of three things about ISCO. One is they seek products that alleviate suffering. The second is they have an operational business side that appears to be stable and slowly growing. That generates both revenue and experience in the mechanics and logistics of a functional producing business (i.e. - not scientific development). The third is they made it to Phase I Human Studies for intracranial transplantation of stem cell derived neural cells and the results are both good and encouraging. That is a major achievement I believe they are not being properly recognized for.

They look to be reaching a Phase II level in the near future. Many in the biotech industry will say new start companies are not even looked at until they are in Phase II. I will bet you even when they reach Phase II they will be under low recognition. It just seems to be that way for them. But some time into Phase II, especially if the operating units continue to expand and provide income, recognition will have to come. One would think....! But it is a strange world. Especially these days. The thing that has always impressed my about ISCO is that they seem to eventually do most of what they say they are going to. The thing that has bothered me the most is how low their cash reserves always ran. The chief insiders always kept it going by diluting, but putting their money in to do it. That seems to be doing the needed thing with confidence. It was nice to see the half million dollar investment purchase of new shares the other day. That added shares, but was not really dilutive since it went for $1.75, which was greater than open market share values. Still not too much dilution in this particular part of the company's phase. I still estimate real effective outstanding shares at somewhere around 30 million shares. If that stayed the same and the operating units continue to grow and expand, and Phase II gets going sooner than later, and Phase II shows good results, I see no reason why the company would not be worth at least 500 million market cap. That is $16.67 per share. That is a lot of ifs and whens. But this looks like at least some kind of positive from here. But, Ya never know. It is all my guess, done with a broken crystal ball by a guy who don't know shit from Shinola.........

Take care.....

Wishing all the best of good buys!

HS

Good news. Especially the fact that nearly 2 years of time has not shown any safety issues or problems associated with possible dying cells and the brains removal of them. So safety looks very good so far. Then the statement;

'The % OFF-Time, which is the time of day when levodopa medication is not performing optimally, and PD symptoms return, decreased an average of 24% for the first cohort and 49% for the second cohort at six months post-transplantation. The same was true for % ON-Time without dyskinesia, which is the time of day when levodopa medication is performing optimally without dyskinesia. The % ON-Time increased an average of 19% for the first cohort and 33% for the second cohort during the same period. The quality of life of the patients as measured by the Parkinson's Disease Quality of Life Score-39 (PDQ-39) Summary Index, improved 15% for the first cohort and 47% for the second cohort at six months post-transplantation.'

is quite encouraging. I agree the need for placebo and more pure efficacy study is needed, which seems likely in Phase II. They mention phase II, but not any real details yet of plan and timing. I trust them to get there in relatively short order after Phase I is completed, as they seem to do what they say they will do on a rather consistent basis. But the fact that the levodopa and dykinesia times improve directly with dosages are supportive findings. That alone could help a lot of patients. Hopefully in an efficacy study stage, dosages will be even higher and stable improvements in lowering PD symptoms during off times will be presented. In any case, as I indicated a long time ago during the primate studies, it is great to get to the human trials where you can actually communicate with the patient for details on how they feel and what they notice about the treatment.

If ISCO's subsidiary work continues to show growth, coupled with the PD treatment clinical phases for the human trials, I am having a hard time seeing this stock remaining under $10/share. Even when you factor in the built-in and potential new dilution, it seems share prices are very undervalued. I wonder if they have a longer range plan to move to a higher recognition board once their platform is proven clinically. I think that is what they need to do at some point in the not so distant future. They seem to do all or most of the reporting necessary to qualify for higher boards, so I don't think it will be a major problem or effort for them to get it done. I assume they are still more focused on subsidiary business health and the clinical studies at the moment, which is fine by me. I would rather have a strong corporate foundation and clinical results heading to a larger board than heading to a larger board in a weaker overall position. That happens all too often with other companies.

Well, overall, I wish there was a little more information on phase II, but very good news none-the-less.

Wishing all the best of good buys!

HS

I hope the press release on Monday Nov 5th will provide a good level of details on the patients. The higher dosage patients will not be in their except for maybe 2 middle dose early info. I would like to see more on the phase II plans and timeline, but I assume press releases on that will not occur until the final 2 phase I patients are transplanted.

Phase I of the clinical study is almost complete. No problems have been noted in this dose escalation safety and preliminary efficacy study of ISC-hpNSC®, intracranially transplanted patients with moderate Parkinson's disease. Phase II appears to be a certainty. This should be good for the stock, but more importantly for those suffering with Parkinsons and TBI (Traumatic Brain Injury, which the science is applicable to) lets hope for even moderate success. Any improvement, even if only to enhance and allow other treatments to be effective, is a big plus for any patient suffering from these debilitating neurological issues. I look forward to reading interim and long term results and to seeing Phase II studies underway. In the biotech world, few seldom take notice until Phase II studies are indeed underway.

Science, for the betterment and improvement in the life of humankind and all that exist on this strange planet of ours. That pale blue dot, called home.

It is going to get very interesting when this moves into Phase II clinical studies, especially if the revenue generating arms continue to grow and expand.

Wishing all the best of good Buys.

HS

Definitely an indication of rising confidence. I assume only 0.285714 million shares were added to the outstanding share count. Certainly not dilutive at this level. Good news, regardless of how you look at it.

Interesting








Can you say basil ganglia.....

US10039794.....Good to see more patent protection. Patents are a pain in the rear. They take a lot of work to write properly. They cost a lot to file for. They cost a lot to maintain. They can cost a lot to defend. They can be rendered worthless should a shrewd competitor find the infamous 'Patent Silver Bullet'. I know, I have 12 patents. Each was a pain in the butt! BUT, patents are essential for technological companies to establish IP with market value. Plus, while a pain in the butt to write, they provide an exercise to focus technical leaders and inventors on the subject, its peripheries, and details in a different manner that is not always done without the effort to produce them.

ISCO may be imperfect like every other company, but they still keep doing what they say they are going to do. They keep slowly building something that if they continue, will not be able to go unnoticed.

ISCO - A small research and development Biotech company that has promising products developed, generates revenue, grows its sales, develops IP through portfolio of patents, follows through on commitments,that lays beneath the radars of most investors and fund managers. Pretty interesting I would say.

HS

Excellent Report. Both revenues and earnings on operations up again. This is getting much closer to funding R&D, mitigating needs for extreme dilution in the future. I still say, this company like all may not be perfect, but they do seem to do most of what they say they are going to. I find that a very rare bird in the low priced small board stock arena. They have also done much more quality of reporting over the years than similar micro cap companies. I hope they move to a bigger board someday soon. The most important thing is that they keep showing steady forward progress like they have. That eventually gets you there, regardless of boards or sentiment.

Yes. I liked it because it provides succinct detail in about as concise manner as possible, which is what a good abstract should. They hit basically everything in it, including detail often glossed over in press releases. It provides trial numbers, trial periods, patient numbers, dosages, observation periods, accurate descriptions of intracranial placements, patient idiopathic values/ranges, patient age group, cell placement technique, regulatory agency information, patient pretrial motor skill rankings, and program funding all in one abstract paragraph.

I found the official abstract to the recent ISCO paper a good synopsis of the current Phase I Clinical Study: reprinted below:

''''In this commentary we discuss International Stem Cell Corporation's (ISCO's) approach to developing a pluripotent stem cell based treatment for Parkinson's disease (PD). In 2016, ISCO received approval to conduct the world's first clinical study of a pluripotent stem cell based therapy for PD. The Australian regulatory agency Therapeutic Goods Administration (TGA) and the Melbourne Health's Human Research Ethics Committee (HREC) independently reviewed ISCO's extensive preclinical data and granted approval for the evaluation of a novel human parthenogenetic derived neural stem cell (NSC) line, ISC-hpNSC, in a PD phase 1 clinical trial (ClinicalTrials.gov NCT02452723). This is a single-center, open label, dose escalating 12-month study with a 5-year follow-up evaluating a number of objective and patient-reported safety and efficacy measures. A total of 6 years of safety and efficacy data will be collected from each patient. Twelve participants are recruited in this study with four participants per single dose cohort of 30, 50, and 70 million ISC-hpNSC. The grafts are placed bilaterally in the caudate nucleus, putamen, and substantia nigra by magnetic resonance imaging-guided stereotactic surgery. Participants are 30–70 years old with idiopathic PD ≤13 years duration and unified PD rating scale motor score (Part III) in the “OFF” state ≤49. This trial is fully funded by ISCO with no economic involvement from the patients. It is worth noting that ISCO underwent an exhaustive review process and successfully answered the very comprehensive, detailed, and specific questions posed by the TGA and HREC. The regulatory/ethic review process is based on applying scientific and clinical expertise to decision-making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines or novel therapies.'''''

Good to see this for LCT. LCT is the research product end. The skin product end has its own value and prospects that are good as well. But with regard to the LCT side, having repeat business to support equipment and production upgrades is a great sign. Skin products have one set of customers where the product satisfaction is as much subjective as it is objective. On the research end, products are scrutinized to the highest level practical by each and every customer. Qualitative and quantitative data and satisfaction standards are more rigid, as products must maintain criterion to satisfactory levels in a consistent and repeatable manner. Otherwise it would jeopardize the downstream research that the customers are attempting, potentially causing huge problems and losses for them. This news is very positive when you look a the underlying meaning of what it is.

I would not put it past them to get this new product done and on the market by the end of the year. I guess we might have to add another product line to this now established hybrid of a company being revenue generating operational plus developmental, plus stage I/II clinical trials. They often get done what they say they are going to do. Kudos to ISCO. Keep building. Eventually the radars will see what you have achieved and reward you and your future patients.

This stock is so far under most radars that news really does not have the reach and thus the impact that it should.

IMHO the cons are:

-they always have low cash on hand.
-the cash burn rate is high (not super high), but still forces negative cash flow.
-due to the above the need for the owners to keep buying stock to fund the extra cash needs, and leads to the potential for significant dilution.
-the board they are on, placement and news reach keeps both good news somewhat hidden from the majority of potential investors.

IMHO the pros are:

-They have real technology that is not a scam and has significant potential in areas of critical medical needs.
-They have accomplished most of what they say they are going to do.
-They have used their developments to support their technology to produce viable products.
-They have real earnings from the marketing branches of their products in cell technology and skin care as separate entities.
-due to the above, they are one of the few developmental/clinical stage biotech companies that have any revenue generating arm at all. Thus some of their cash burn is funded through division earnings and they additionally gain valuable marketing experience and contacts.
-They have a multitude of patents, some more valuable than others. Patents are costly to get and maintain, but add to a companies intellectual property value and can be the key to future success or buyout value.
-their clinical stage I and II studies are done through a world renowned neurological research facility. (no company that has scam technology would be able to get their foot in the door with such reputable organizations)

It is one of the things I like about this company. It keeps probing for technology applications. Then often, making something tangible out of it. From their latest: """Supplementation of Specific Carbohydrates Results in Enhanced Deposition of Chondrogenic-Specific Matrix during Mesenchymal Stem Cell Differentiation,” discusses a new scalable system developed by ISCO that permits the generation of functional human cartilage tissue derived from the patient's own skin or fat tissue."""

This company needs to move from the current board to board with a more full scope radar screen.

I have followed them for years. Been caught in major wipe-out level dilution. But over the years, they seem to keep doing a lot of what they say they are going to do. That is rather rare, even for the big boys. IMHO ISCO is undervalued.....

Pretty good report. I hope the sales side continues to improve. It would be great if they could fully fund R&D with proceeds from operating units. With such decreases in cash burn, it might be practical to assume some future quarters could show increases in cash burn. Unless sales increase at a higher rate. However, all a good thing so far as revenues do seem to have slow but steady growth.

FROM 2018 1st Quarter Reporting:

Q1 2018 Financial Highlights

Consolidated revenue for the first quarter of 2018 was $2.6 million, an increase of 30% compared to the consolidated revenue of $2.0 million for the first quarter of 2017.
Combined operating income for the quarter ended March 31, 2018 from our two wholly owned revenue generating subsidiaries was $631,000, an increase of 10% compared to $572,000 in the first quarter of 2017.
Average net cash used in operating activities, excluding capital expenditures and patent costs, was approximately $16,000 per month during the three months ended March 31, 2018, a decrease of 92%, compared to $190,000 per month for the same period in 2017.
Net loss for ISCO was $830,000 for the first quarter of 2018 compared to a net loss of $3.1 million for the first quarter in 2017, a decrease of 73%.
Recent Clinical Trial Highlights

The 2nd cohort of patients in the clinical trial for Parkinson's disease was successfully transplanted with 50,000,000 ISC-hpNSC® cells.
Data Safety Monitoring Board (DSMB), a group of experts monitoring the clinical trial of ISC-hpNSC®, has reviewed the safety data from the 2nd cohort in the clinical trial. The DSMB has authorized the clinical trial to move forward with accelerated enrollment and dose escalation to the 3rd cohort. Recruitment for the 3rd cohort will begin immediately, with patients receiving a higher dose of 70,000,000 ISC-hpNSC®.
United States Patent and Trademark Office (USPTO) has granted the Company a key patent on the method used to manufacture ISC-hpNSC, which are administered in ISCO's ongoing Parkinson's disease clinical trial, and which can potentially be utilized in therapies to treat traumatic brain injury and stroke.
Presented Interim Clinical Results at the American Academy of Neurology in Los Angeles, CA.

Edison also said a BW boiler was the best boiler God allowed man to make and that was shown to be true. GO ISCO!

Agreed if it was an old Established cosmetics company, but it is not. Only part is cosmetics. The other half is laboratory cell technology. If ISCO stopped all R&D, they may have losses for a period of adjustment, but their structure would change to avoid peripheral and parasitic costs that are in-part intertwined at the moment.

Well actually it is effectively higher than you see reported for the reasons mr negative says (in part). The preferred shares and warrants do have an impact on outstanding shares in the long run. I like to be more conservative and assume what might be more likely as time goes by. Even with my conservative approach, I have had the outstanding shares shoot right by my conservative estimates in many cases on other investments. I only suggest that buyers beware of the latest reported share statistics when considering investments. Especially in companies that are in any way developmental. I can almost guarantee you there will be at least some dilution. Just my opinion though. Approach your investments as you see fit. Best of luck though. It is nice to see positive (even if partially wishful) people on the message boards. The negativity in this world is getting a little old.